Karen Jacobson-Sive

Combining capivasertib, an AKT inhibitor, with venetoclax, an BCL-2 inhibitor, provoked promising responses in patients with diffuse large B-cell lymphoma (DLBCL), according to a study in Nature.1 Researchers conducted an in vitro combination screen across a panel of 26 DLCBL […]

B-cell activating factor receptor (BAFF-R) chimeric antigen receptor (CAR) T-cell therapy incited cytotoxic effects on both chronic lymphocytic leukemia (CLL) cell lines and primary B cells derived from CLL patients, according to a study published in MedComm.1 The CAR T